Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 10:00am ET. The event will be held virtually, and a live audio webcast will be accessible on the company's website. Protara focuses on developing transformative therapies for cancer and rare diseases, with lead programs including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.

News Market Reaction – TARA

+2.05%

+2.05% Session move

In the trading session that priced this news, TARA gained 2.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference being held in a virtual setting on Wednesday, March 17, 2021 at 10:00am ET.

A live audio webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived on the Company’s website for 90 days following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

What is the date of Protara Therapeutics' fireside chat?

Protara Therapeutics will participate in a fireside chat on March 17, 2021.

What is the stock symbol for Protara Therapeutics?

The stock symbol for Protara Therapeutics is TARA.

Where can I watch the Protara Therapeutics fireside chat?

The fireside chat can be watched live on the Protara website under the Events and Presentations section.

What are the main therapies being developed by Protara?

Protara is developing TARA-002 for bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.

How long will the Protara webcast be available after the event?

The webcast will be archived for 90 days after the presentation.